Joe Tippens Protocol: Fenbendazole, Ivermectin, and Repurposed-Drug Cancer Research

The Joe Tippens protocol has become one of the most-discussed anecdotal cancer cases of the past decade. In 2016, Joe Tippens - a sales executive diagnosed with stage 4 small cell lung cancer that had metastasized throughout his body - was given roughly three months to live. After a veterinarian friend mentioned a Merck research scientist whose terminal cancer reportedly resolved on a dog dewormer, Tippens began taking fenbendazole alongside several supportive supplements. Within three months, scans showed no detectable cancer.

His story spread through the My Cancer Story Rocks blog and Facebook groups, eventually spawning what is now called the Joe Tippens protocol. Later iterations added ivermectin, another repurposed antiparasitic with a growing body of preclinical anticancer literature. This article reviews the protocol as it is most commonly reported, the published research on each compound's anticancer mechanisms, and what the literature does and does not support.

Research framing. This is an educational review of an anecdotal protocol and the published research around repurposed antiparasitic drugs in oncology. Nothing here is medical advice. The compounds discussed are sold strictly as research reagents and are not approved for human consumption. See our research-use-only disclaimer.

The Original Joe Tippens Protocol (As Most Commonly Reported)

The protocol as Tippens described it - and as it has been replicated in subsequent anecdotal accounts in the same Facebook groups and on the My Cancer Story Rocks blog - consists of four core elements reported over a roughly six-week cycle. Tippens himself stayed on the protocol for approximately six weeks before reporting clearance on scans.

Important framing. The doses above are summarized from publicly available anecdotal accounts and research-forum discussions. They are not recommendations, not endorsed by any medical authority, and not supported by any randomized clinical trial. Fenbendazole is a veterinary medication not approved for human use. Self-administration of any of these compounds for cancer treatment is dangerous and may interfere with prescribed oncology care.

Why Antiparasitics? The Repurposed-Drug Rationale

Repurposed-drug oncology - testing established, off-patent medications for anticancer activity - is a serious area of academic research. Benzimidazoles (the class containing fenbendazole, mebendazole, and albendazole) and avermectins (the class containing ivermectin) have both shown preclinical anticancer activity across multiple tumor types.

Fenbendazole mechanism of interest

Fenbendazole is a benzimidazole anthelmintic developed for veterinary use against intestinal parasites. Its anticancer activity in cell-line and animal models appears to involve several overlapping mechanisms:

• Microtubule disruption. Fenbendazole binds to tubulin and prevents microtubule polymerization - the same mechanism exploited by the taxane chemotherapeutics. Cancer cells, with their high mitotic rate, are particularly sensitive to mitotic spindle disruption.
• p53 pathway reactivation. In p53-wild-type cells, fenbendazole has been observed to stabilize and activate p53, the master tumor-suppressor protein.
• Glucose uptake inhibition. Fenbendazole appears to interfere with GLUT4-mediated glucose uptake, depriving glycolytic tumor cells of fuel.
• Autophagy and apoptosis. Multiple published studies report fenbendazole inducing both autophagic and apoptotic cell death in cancer cell lines.

A 2018 paper in Scientific Reports (Dogra et al.) demonstrated fenbendazole's anticancer activity in non-small-cell lung cancer cell lines, including the H460 line that models Tippens's own diagnosis.

Ivermectin mechanism of interest

Ivermectin is an avermectin antiparasitic discovered in the 1970s and used at scale in humans for river blindness, scabies, and strongyloidiasis (it has been administered billions of times worldwide with a strong safety profile). Its preclinical anticancer literature includes:

• PAK1 inhibition. Ivermectin downregulates PAK1, a kinase frequently overexpressed in cancers and involved in proliferation, invasion, and metastasis.
• WNT/β-catenin pathway suppression. WNT signaling drives stemness and proliferation in many cancers; ivermectin has been reported to dampen this pathway in colorectal, breast, and leukemia models.
• Mitochondrial dysfunction and autophagy. A 2019 paper in Cell Death and Disease showed ivermectin inducing autophagy-mediated cell death in glioma cells at clinically achievable concentrations.
• MDR pump inhibition. Ivermectin has been observed to inhibit P-glycoprotein, the multi-drug-resistance pump that pumps chemotherapy drugs out of cancer cells.

The clinical literature in humans is dominated by case reports, retrospective series, and a small number of phase 1/2 trials, mostly in hematologic malignancies. No phase 3 oncology trial has yet established ivermectin as a standalone cancer therapy.

The Combined "Joe Tippens + Ivermectin" Stack (Schedule Reported in Forums)

When the protocol has been adapted in research forums to add ivermectin, the most-reported schedule pattern is summarized below. This is provided for research-literature documentation only.

Dosing variations seen in research forum discussions

• Higher-dose fenbendazole. Some accounts describe 444 mg/day (two capsules) on the on-days, citing rodent studies that used proportionally higher mg/kg doses.
• Weight-adjusted ivermectin. Doses reported range from 0.2-0.4 mg/kg per dose for general antiparasitic context, with some research-context discussions reporting up to 0.6 mg/kg.
• Continuous fenbendazole. Some accounts skip the pulsed schedule and report 222 mg daily, citing the absence of a hard mechanistic rationale for the 3-on/4-off split.
• Mebendazole substitution. Mebendazole (a human-approved benzimidazole) has been discussed as a substitute for fenbendazole at 100-200 mg/day in research contexts, based on better-characterized human pharmacokinetics.

Reminder. All doses above are summaries of anecdotal accounts and research-forum discussions. None are clinically validated for cancer treatment. None are endorsed.

What the Published Evidence Actually Supports

To stay honest about what is and is not known:

• Strong: preclinical (cell-line and rodent) evidence for anticancer activity of both fenbendazole and ivermectin, across multiple mechanisms and tumor types. This is a real, peer-reviewed body of literature.
• Moderate: human safety data for ivermectin (decades of antiparasitic use). Human safety data for short-course fenbendazole is sparse but no signal of serious harm has emerged in the case-report literature.
• Weak: human efficacy data in oncology for either compound. Joe Tippens's case is anecdotal. Many similar anecdotal cases exist; many other anecdotal cases of protocol failure exist but receive less attention. Randomized controlled trials are essentially absent.
• Hypothesis-generating: the combination protocol. There is no published clinical data on fenbendazole + ivermectin specifically as a combination regimen in humans.

For researchers interested in this space, the most actively recruiting clinical trial categories involve mebendazole (human-approved) in glioma and pediatric brain tumors, and ivermectin in COVID-19-adjacent oncology indications.

FAQ

What is the Joe Tippens protocol?

The Joe Tippens protocol is an anecdotal repurposed-drug cancer regimen built around the veterinary antiparasitic fenbendazole, taken 222 mg/day on a 3-days-on, 4-days-off schedule, alongside vitamin E succinate (400-800 IU), CBD oil (25 mg), and often curcumin. Many adherents add ivermectin at 12-24 mg dosed on the off-days. It is named for Joe Tippens, who in 2016 reported complete resolution of stage 4 small cell lung cancer after following a similar regimen.

What fenbendazole dose is reported in the Joe Tippens protocol?

The most commonly cited reported dose is 222 mg of fenbendazole per day (one 1g sachet of Panacur C 22.2%, or one 222 mg capsule), with reports indicating it was taken with a fatty meal. The reported schedule is 3 consecutive days on, 4 days off. Reported variations include continuous daily dosing or doubling to 444 mg on on-days. This is descriptive documentation of an anecdotal protocol - not a recommendation. Fenbendazole is a veterinary medication not approved for human use.

What ivermectin dose is reported in adapted versions of the protocol?

Research-forum reports of ivermectin added to the protocol cluster around 12-24 mg per dose (approximately 0.2-0.4 mg/kg for an 80 kg adult), 2-3 times per week on fenbendazole off-days. Higher research-context doses up to 0.6 mg/kg have been reported. Ivermectin's long half-life means daily dosing is generally not described in these accounts. None of this is clinically validated for cancer treatment.

What is the science behind antiparasitics in cancer research?

Both benzimidazoles (fenbendazole, mebendazole, albendazole) and avermectins (ivermectin) have multiple preclinical anticancer mechanisms documented in peer-reviewed literature - microtubule disruption, p53 activation, glucose-uptake inhibition, PAK1 downregulation, WNT/β-catenin suppression, and induction of autophagic cell death. The mechanisms are well established in cells and animals; human clinical efficacy data is much weaker.

Is the Joe Tippens protocol safe?

Ivermectin has a strong human safety profile from billions of doses given for antiparasitic indications. Fenbendazole has decades of veterinary safety data and a small but growing human case-report literature without major safety signals at typical Joe Tippens doses. That said, neither compound is approved for human cancer treatment, all dosing is off-label, and interactions with chemotherapy or other medications have not been thoroughly characterized.

How long do people stay on the Joe Tippens protocol?

Joe Tippens himself reported about 6 weeks before scans showed clearance. Many followers report staying on the protocol for 3-12 months, with some cycling on/off in 6-week blocks indefinitely. There is no consensus protocol length because there is no controlled trial data.

Closing Note

The Joe Tippens protocol sits at an unusual intersection: a real body of peer-reviewed preclinical research on repurposed antiparasitics in oncology, layered on top of a single highly visible anecdotal case, dressed up as a defined regimen. The mechanisms are scientifically credible. The human efficacy data is not. This article exists as a primer on what the protocol is, what dosing schedules are most commonly reported, and what the research literature actually supports - so that researchers exploring this space have an honest starting point rather than mythology.

Research compounds discussed in this article are sold strictly for laboratory study and are not approved for human consumption. For our 12 mg Ivermectin reference standard (50 tablets per bottle, HPLC-verified), see Ivermectin (12mg x 50).